Fish oil derivative may calm heart inflammation and stabilize plaques
NCT ID NCT07641257
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether icosapent ethyl, a purified fish oil medication, can reduce inflammation and improve heart structure in people with coronary artery disease. Researchers will follow 420 patients for one year, comparing those who receive standard care plus icosapent ethyl to those on standard care alone. They will measure blood markers of inflammation and use heart imaging to see if the drug helps stabilize fatty plaques and prevent harmful changes to the heart's shape.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- icosapent ethyl
- What this could lead to
- If it works, this could show that adding icosapent ethyl to standard care helps lower inflammation and stabilize heart plaques, potentially reducing future heart events.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be less reliable. It is also relatively small and short-term, so any benefits may not be confirmed or lasting.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 420 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
May 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population consists of adult patients (aged 18 years and older) diagnosed with either acute coronary syndrome (ACS) or chronic coronary syndrome (CCS) who present to the cardiology inpatient wards or outpatient clinics of the participating medical centers. These are real-world patients who have elevated fasting triglyceride levels (\>= 1.7 mmol/L) and are routinely receiving standard-of-care cardiovascular therapies, including statin therapy. Depending on their routine clinical prescriptions determined by their treating physicians, they are either receiving Icosapent ethyl (IPE) as an add-on therapy or continuing with standard of care alone.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age 18 years and older, of any sex. * Definite diagnosis of chronic coronary syndrome (CCS) according to the Chinese Guidelines for the Diagnosis and Management of Patients with Chronic Coronary Syndrome, or acute coronary syndrome (ACS) according to the 2025 ACC/AHA/ACEP/NAEMSP/SACI Guideline for the Management of Acute Coronary Syndromes. * Laboratory evaluation showing fasting triglycerides (TG) \>= 1.7 mmol/L. * Ability to fully understand the study purpose, voluntary participation, and provision of signed written informed consent. Exclusion Criteria: * Women who are planning a pregnancy, currently pregnant, or lactating. * Known hypersensitivity or allergic reaction to the active ingredient of icosapent ethyl (IPE) or any of its excipients (applicable to patients in the exposure cohort). * Diagnosed with major life-threatening conditions such as malignant tumors, end-stage lung disease, or advanced neurodegenerative diseases, with a life expectancy of less than 12 months. * Concurrent participation in any other interventional clinical trial involving investigational drugs or medical devices. * Any other condition or severe non-compliance that, in the judgment of the investigator, makes the patient unsuitable for enrollment in this study.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute coronary syndromes (ACS) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can heart stent patients go home in 6 hours?
- Can AI read heart scans to predict the next heart attack?
- Can a new drug cool the hidden inflammation that fuels heart disease?
- New CT scanner aims to cut unnecessary heart procedures
- Can a berry extract help athletes bounce back after brutal workouts?
- Can PET scans reveal hidden heart inflammation after a stroke?